GlaxoSmithKline Biologicals

• A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine when Given to Healthy Children 3 Month… Not authorised
  2024-516635-27-00 Phase III 2 countries GSKVX000000025896; VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED); VARICELL…
• A study on the immune response and safety of an investigational chickenpox vaccine and a marketed measles, mumps and rubella vaccine when ad… Recruiting
  2024-518840-18-00 Phase III 8 countries GSKVX000000025896; MEASLES VIRUS EDMONSTON-SCHWARZ STRAIN (LIVE, ATTENUATED) PRO…
• A study evaluating persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccinatio… Recruiting
  2024-519730-23-00 Phase II 3 countries RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-…
• A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zos… Recruiting
  2022-502784-37-00 Phase II 6 countries GSKVX000000014593
• A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia… Recruiting
  2025-524944-37-00 Phase IV 1 country RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
• A phase IV trial of Shingrix on incident dementia diagnosis in adults aged ≥76 years in Finland Recruiting
  2025-524598-17-00 Phase IV 1 country RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
• A study on the immune response and safety of an investigational chickenpox vaccine when given to healthy children 12 to 15 months of age. Recruiting
  2024-515869-33-00 Phase III 4 countries GSKVX000000025896; VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED); VARICELL…
• A study on the safety of an investigational chickenpox vaccine, when given to healthy children, 12 to 15 months of age. Recruiting
  2024-515868-31-00 Phase III 5 countries GSKVX000000025896; VARICELLA VIRUS OKA/MERCK STRAIN (LIVE, ATTENUATED); VARICELL…
• A study to assess the immune response and safety of a vaccine against influenza in adults 18 years of age and older Ended
  2025-522599-97-00 Phase II 1 country GSKVX000000034794, GSKVX000000034798, GSKVX000000048110, GSKVX000000048111, GSKV…
• A study on the safety, and immunogenicity of a UTI vaccine in adults 18 through 64 years of age and clinical efficacy in females 18 through … Ended
  2024-519319-32-00 Phase I (FiH) 2 countries GSKVX000000044501; GSKVX000000046019
• An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended
  2023-509762-38-00 Phase III 7 countries RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-…
• A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended
  2023-505255-51-00 Phase III 8 countries RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
• A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different… Ended
  2023-504301-37-00 Phase II 1 country MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE …
• Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 yea… Ended
  2024-512291-34-00 Phase III 2 countries RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-…
• A Phase 3 study to assess the immune response and safety of rMenB+OMV NZ in primed healthy participants (10 to 20 years old) Ended
  2024-519549-31-00 Phase III 3 countries RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. CO…
• A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults. Ended
  2024-512846-41-00 Phase I 1 country
• A study on the immune response, safety and the occurrence of RSV-associated respiratory tract illness after administration of RSV OA vaccine… Ended
  2023-509455-13-00 Phase III/IV 3 countries RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-…
• A study on the immune response and safety of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccin… Ended
  2023-510196-59-00 Phase III 3 countries RAXTOZINAMERAN; RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABIL…
• A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased … Ended
  2023-510190-34-00 Phase III 1 country RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-…
• A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18… Ended
  2024-510571-37-00 Phase I (FiH) 4 countries GSKVX000000030810; GSKVX000000030825; GSKVX000000030918
• A study on the immune response and safety of an RSV vaccine when given to adults 18 years of age and above who received lung or kidney trans… Ended
  2023-503951-81-00 Phase II 3 countries RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-…
• Safety and efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of ag… Ended
  2022-500883-37-00 Phase I (FiH) 3 countries
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat… Ended
  2022-501988-40-00 Phase III 3 countries PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197 ADSORBED ON ALUMINIU…
• A study on the immune response and safety of a combined measles, mumps, rubella, chickenpox vaccine compared to a marketed combined vaccine,… Ended
  2022-501564-18-00 Phase II 2 countries RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN WI-38 HUMAN D…

Showing 1–24 of 29 trials